Aurobindo Pharma makes a decent start to FY18

With 3 key launches in June quarter, analysts have upgraded their earnings estimate

In a sector weighed down by bad news for some time, Aurobindo Pharma has done relatively better. In the past month and a half, the stock has outperformed its larger pharma peers on positive news flow. And, there could be more gains.

The company made a good start to 2017-18, having got approvals for key generic launches in the US. This holds significance, with the pricing pressure on generics in the US, the world's largest health care market.

The company has also seen the completion of a series of successful inspections at many of its facilities here in recent months by the